Healthcare Industry News: CoreValve
News Release - January 7, 2008
CoreValve announces that more than 500 high-risk patients have been treated with its ReValving(R) System for percutaneous aortic valve replacement (PAVR)Company's 18-French ReValving(R) System, which received European regulatory clearance in mid-2007, is the smallest PAVR system in the clinic
IRVINE, Calif.--(HSMN NewsFeed)--CoreValve (www.CoreValve.com) announced today that the expanded clinical evaluation of its ReValving® System for percutaneous aortic valve replacement (PAVR) in high-risk patients with aortic stenosis is enrolling patients at 32 sites in 11 European countries. The ReValving® System procedures can be performed under local anesthesia, without the need for surgical cut-down/repair, and without hemodynamic support or artificially accelerating the heart rate.
CoreValve, Inc., is headquartered in Irvine, Calif. Its proprietary ReValving® System allows both percutaneous aortic valve replacement (PAVR) and transapical aortic valve replacement (TAVR) and is intended to provide an alternative to open-heart surgery. The ReValving® System procedures are performed on the beating heart without cardiac assistance or rapid pacing, and may result in less trauma to the patient. This technology may also offer substantial cost-savings to the healthcare system. The catheter-based technology includes a proprietary framed/self-expanding tissue heart valve that is specifically designed and engineered for transcatheter delivery. For more information about CoreValve, visit the Company’s Web site at www.CoreValve.com.
(Caution: the CoreValve ReValving System will not be available in the USA for clinical trials or for sale until further notice.)
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.